Difference between revisions of "Cohn and Wolfe Ltd"

From Powerbase
Jump to: navigation, search
(Ghost-written journal articles)
(PRCA lobbying register)
 
(23 intermediate revisions by 6 users not shown)
Line 1: Line 1:
'''Cohn & Wolfe''' - a subsidiary of [[WPP]] - describes itself as a "strategic marketing public relations firm dedicated to creating, building and protecting the world&#39;s most prolific brands."<ref>[http://www.cohnwolfe.com/Content.aspx?NodeId=6 Cohn & Wolfe website]</ref> It has offices all over the world including UK, US, throughout Europe, Latin America, Middle East, and the Asia Pacific region.
+
{{Template:Foodspin badge}}
 +
{{Template:Pharma_Portal_badge}}
 +
'''Cohn and Wolfe''' - a subsidiary of [[WPP]] - describes itself as a "strategic marketing public relations firm dedicated to creating, building and protecting the world&#39;s most prolific brands."<ref>[http://www.cohnwolfe.com/Content.aspx?NodeId=6 Cohn & Wolfe website]</ref> It has offices all over the world including UK, US, throughout Europe, Latin America, Middle East, and the Asia Pacific region.
 +
 
 +
The firm claims to be an agency for the 'new communications landscape'. It is a global public relations agency with 50 offices in major markets around the world. They 'offer a powerful combination of breakthrough, brand-building creativity and pioneering digital and social media strategies.' <ref>Cohn & Wolfe. [http://www.cohnwolfe.com/en/about-us Cohn & Wolfe About Us]. Accessed on 24 October 2009.</ref>
 +
 
 +
The firm's 10 industry practices are Consumer Branding, Corporate, Digital, Energy, Entertainment, Healthcare, Public Affairs, Sports Marketing, Sustainability and Technology.
  
 
It offers clients 'strategic partnerships' with other WPP companies, including [[Quinn Gillespie]], a lobbying firm.
 
It offers clients 'strategic partnerships' with other WPP companies, including [[Quinn Gillespie]], a lobbying firm.
 +
 +
Cohn and Wolfe has also teamed up with lobbying firm [[Open Road]] in the UK. <ref>APPC register, 12 2006 - 03 2007</ref>
 +
 +
==Healthcare==
 +
 +
Cohn and Wolfe recognise that Healthcare PR is changing and encourage clients to search for new models in communicating effectively to healthcare professionals, consumers and payors. The agency in turn creates 'bold creative strategies' with a focus on providing consumers with more information to take more active roles in their healthcare. According to C & W: 'As public relations professionals, it's our job to really understand the conversations happening among our clients' customers, patients, physicians, policy makers, and payors. Much of today's conversation is happening in social media channels, and this is true for healthcare.'<ref>Cohn & Wolfe. [http://www.cohnwolfe.com/en/practice/healthcare/overview Cohn & Wolfe Practices]. Accessed on 24 October 2009.</ref> The agency claims to be an expert in working in the complex environment where healthcare providers, patients, caregivers, advocacy groups and manufacturers engage in digital communications channels like social communities, blogs, and various audio/video sites.
  
 
==Dabbling with fake blogging==
 
==Dabbling with fake blogging==
  
Fake blogs - a form of viral marketing in which PR or advertising agencies attempt to generate interest in their client's product by creating a fictional character on the internet - are drawing criticism from real bloggers. The Cohn & Wolfe PR firm had to apologize in 2005 after "using a fictional character to leave a series of thinly veiled advertisements on blogs and other websites. A number of websites were hit last week with messages from Barry Scott," a fictional spokesman for a British household cleaning product.  
+
Fake blogs - a form of viral marketing in which PR or advertising agencies attempt to generate interest in their client's product by creating a fictional character on the internet - are drawing criticism from real bloggers. Cohn & Wolfe apologized in 2005 after "using a fictional character to leave a series of thinly veiled advertisements on blogs and other websites. A number of websites were hit last week with messages from Barry Scott," a fictional spokesman for a British household cleaning product.  
  
 
British blogger Tom Coates was especially outraged and called it "a new low for marketers" after he wrote an emotional account of his relationship with his father, and then received comment spam from "Barry Scott" disguised as condolences. Coates replied: "My view was that any right-thinking person would view trying to market your product on such a post as revolting, corrupt, cynical, disgusting, sick and dishonourable."<ref>Tom Coates, [http://www.plasticbag.org/archives/2005/09/on_cillit_bang_and_a_new_low_for_marketers.shtml On Cillit Bang and a new low for marketers...]", ''Plasticbag.org'', September 30, 2005.</ref><ref>[http://www.plasticbag.org/archives/2005/10/an_apology_from_the_cillit_bang_team.shtml An apology from the Cillit Bang team...]", ''Plasticbag.org'', October 4, 2005</ref><ref>Bobbie Johnson, "[http://www.guardian.co.uk/uk_news/story/0,,1585687,00.html Cleaner caught playing dirty on the net]", ''The Guardian'' (UK), October 6, 2005</ref>
 
British blogger Tom Coates was especially outraged and called it "a new low for marketers" after he wrote an emotional account of his relationship with his father, and then received comment spam from "Barry Scott" disguised as condolences. Coates replied: "My view was that any right-thinking person would view trying to market your product on such a post as revolting, corrupt, cynical, disgusting, sick and dishonourable."<ref>Tom Coates, [http://www.plasticbag.org/archives/2005/09/on_cillit_bang_and_a_new_low_for_marketers.shtml On Cillit Bang and a new low for marketers...]", ''Plasticbag.org'', September 30, 2005.</ref><ref>[http://www.plasticbag.org/archives/2005/10/an_apology_from_the_cillit_bang_team.shtml An apology from the Cillit Bang team...]", ''Plasticbag.org'', October 4, 2005</ref><ref>Bobbie Johnson, "[http://www.guardian.co.uk/uk_news/story/0,,1585687,00.html Cleaner caught playing dirty on the net]", ''The Guardian'' (UK), October 6, 2005</ref>
Line 13: Line 25:
 
Cohn & Wolfe was at the centre of a scandal in which [[Eli Lilly]] (a Cohn & Wolfe client) officials ghost-wrote studies for medical journals. The articles plugged an Eli Lilly drug, the antipsychotic [[Zyprexa]], and were published under the names of credentialed scientists.<ref>Elizabeth Lopatto, Jef Feeley and Margaret Cronin Fisk, "[http://www.bloomberg.com/apps/news?pid=20601109&sid=aVvfe.v1k_VY Eli Lilly "ghost-wrote" articles to market Zyprexa, files show]", Bloomberg, 123 June 2009, accessed 23 June 2009</ref>  
 
Cohn & Wolfe was at the centre of a scandal in which [[Eli Lilly]] (a Cohn & Wolfe client) officials ghost-wrote studies for medical journals. The articles plugged an Eli Lilly drug, the antipsychotic [[Zyprexa]], and were published under the names of credentialed scientists.<ref>Elizabeth Lopatto, Jef Feeley and Margaret Cronin Fisk, "[http://www.bloomberg.com/apps/news?pid=20601109&sid=aVvfe.v1k_VY Eli Lilly "ghost-wrote" articles to market Zyprexa, files show]", Bloomberg, 123 June 2009, accessed 23 June 2009</ref>  
  
Lilly sought to make Zyprexa “the number one selling psychotropic in history,” Bloomberg.com reports. In order to make the drug attain its "sales goal", Eli Lilly hired ghost-writers to prepare the articles for publication in medical journals. Documents unsealed as a result of a lawsuit against Eli Lilly for overpricing its drugs reveal that Cohn & Wolfe played a PR role in this process.  
+
Zyprexa is controversial because it is administered by internal injection and is sometimes given forcibly to psychiatric patients. It is also controversial because of its severe listed side-effects, which can include diabetes and tardive dyskinesia (involuntary movements of the mouth, tongue, jaw, or eyelids). The latter side-effect is in some cases irreversible.<ref>[http://www.medicinenet.com/olanzapine/article.htm Zyprexa, Zydis], MedicineNet.com, accessed 23 June 2009</ref>
 +
 +
In spite of these drawbacks, Lilly sought to make Zyprexa “the number one selling psychotropic in history,” Bloomberg.com reports. In order to make the drug attain its "sales goal", Eli Lilly hired ghost-writers to prepare the articles for publication in medical journals. Documents unsealed as a result of a lawsuit against Eli Lilly for overpricing its drugs reveal that Cohn & Wolfe played a PR role in this process.  
  
 
Bloomberg.com reports:  
 
Bloomberg.com reports:  
Line 22: Line 36:
  
 
==Rebranding shyness as national disease problem==
 
==Rebranding shyness as national disease problem==
According to a story by Martha Rosenberg on AlterNet, Cohn & Wolfe rebranded shyness as a disease that requires medication - with:
+
According to a story by Martha Rosenberg on AlterNet, Cohn & Wolfe is credited with rebranding shyness as a disease that requires medication with the drug [[Paxil]]:
:Slick PR firm Cohn and Wolfe is credited with vaulting "shyness" to a national psychiatric problem, the answer for which is Paxil, and creating faux grassroots patient groups like Freedom From Fear to push their clients' drugs.<ref>Martha Rosenberg, [http://www.alternet.org/story/70013/?ses=9c20109167b5d1e490be29eb65e29dbb Are You One of Big Pharma's Lab Animals?], AlterNet, 7 December 2007, accessed June 23 2009</ref>
+
:Slick PR firm Cohn and Wolfe is credited with vaulting "shyness" to a national psychiatric problem, the answer for which is Paxil, and creating faux grassroots patient groups like [[Freedom From Fear]] to push their clients' drugs.<ref>Martha Rosenberg, [http://www.alternet.org/story/70013/?ses=9c20109167b5d1e490be29eb65e29dbb Are You One of Big Pharma's Lab Animals?], AlterNet, 7 December 2007, accessed June 23 2009</ref>
  
Paxil is an antidepressant drug of the SSRI (selective serotonin reuptake inhibitor) type, manufactured by [[GlaxoSmithKline]].
+
Paxil is an antidepressant drug of the SSRI (selective serotonin reuptake inhibitor) type, manufactured by [[GlaxoSmithKline]]. It became controversial after a Wyoming, USA lawsuit in 2001 brought against GlaxoSmithKline. The jury decided that Paxil was implicated in a tragic case where a 60-year-old man, Donald Schell, shot and killed his wife, daughter and granddaughter and then himself after taking Paxil for only two days. The jury, assisted by the expert testimony of Dr David Healy, a well known critic of SSRIs, concluded that Paxil "can cause some people to become homicidal and/or suicidal." GlaxoSmithKline was ordered to pay the plaintiffs, members of Mr Schell's family, $8 million.<ref>Evelyn Pringle, "[http://www.lawyersandsettlements.com/articles/00353/SSRI_Warning.html Uphill Battle - Warning Pharma Customers about Dangers of SSRIs]", lawyersandsettlements.com, 29 September 2006, accessed 23 June 2009</ref>
  
 
==Clients==
 
==Clients==
 +
===PRCA lobbying register===
 +
====December 2015-Feburary 2016====
 +
[[3M]] | [[Asia Pulp and Paper]] | [[Ferrero UK Ltd]] | [[Lloyds Banking Group]] | [[Scottish Widows]] | [[Warburtons]] <ref name="PRCA">[http://www.prca.org.uk/assets/files/PublicAffairsRegister(2).pdf Cohn and Wolfe clients, Dec15-Feb16], ''PRCA'', accessed 4 May 2016</ref>
 +
 +
====September 2015-November 2015====
 +
[[3M]] | [[Asia Pulp and Paper]] | [[Ferrero UK Ltd]] | [[Lloyds Banking Group]] | [[Scottish Widows]] | [[Warburtons]] <ref name="Sep15">[http://www.prca.org.uk/assets/files/PublicAffairsRegister%20(1).pdf Cohn and Wolfe Ltd client list, Sep-Nov15], ''PRCA'', accessed 5 May 2016</ref>
 +
 +
====June 2015-August 2015====
 +
[[3M]] | [[Asia Pulp and Paper]] | [[Ferrero UK Ltd]] | [[Lloyds Banking Group]] | [[Scottish Widows]] | [[Warburtons]]  <ref name="Jun15">[http://www.prca.org.uk/assets/files/PublicAffairsRegister(1).pdf Cohn and Wolfe Ltd client list, Jun-Aug15], ''PRCA'', accessed 5 May 2016</ref>
 +
 +
====March 2015-May 2015====
 +
[[3M]] | [[Asia Pulp and Paper]] | [[Ferrero UK Ltd]] | [[Lloyds Banking Group]] | [[Scottish Widows]] | [[Warburtons]] <ref name="Mar15">[http://www.prca.org.uk/assets/files/PublicAffairsRegister%20(5).pdf Cohn & Wolfe Ltd client list, Mar-May15], ''PRCA'', accessed 5 May 2016</ref>
 +
 +
===2009===
 
As of June 2009 O'Dwyer's Directory of PR Firms lists Cohn & Wolfe clients as including:<ref>[http://www.odwyerpr.com/pr_firms_database/prfirm_detail.htm?prid={A1CD620F-D29C-40AE-BE27-BD8FA0276026} Cohn & Wolfe], O'Dwyer's, accessed 17 June 2009</ref>
 
As of June 2009 O'Dwyer's Directory of PR Firms lists Cohn & Wolfe clients as including:<ref>[http://www.odwyerpr.com/pr_firms_database/prfirm_detail.htm?prid={A1CD620F-D29C-40AE-BE27-BD8FA0276026} Cohn & Wolfe], O'Dwyer's, accessed 17 June 2009</ref>
*[[3M]] | [[ADP]] | [[American Foundation for Suicide Prevention]] | [[Chevron Texaco]] | [[Coca-Cola]] | [[Colgate-Palmolive]] | [[Danone]] | [[Diageo]] | [[DuPont]] | [[Eli Lilly & Co.]] | [[Epson]] | [[Hewlett-Packard]] | [[Hilton Hotels]] | [[Illycafe]] | [[Intel]] | [[M&M/Mars]] | [[McDonald's]] | [[Merck]] | [[Novartis]] | [[PGA]] | [[Pfizer]] | [[Seagram's]] (Absolut) | [[Sears]] | [[Smuckers]] | [[Sony]] | [[Taco Bell]]
+
[[3M]] | [[ADP]] | [[American Foundation for Suicide Prevention]] | [[Chevron Texaco]] | [[Coca-Cola]] | [[Colgate-Palmolive]] | [[Danone]] | [[Diageo]] | [[DuPont]] | [[Eli Lilly]] & Co. | [[Epson]] | [[Hewlett-Packard]] | [[Hilton Hotels]] | [[Illycafe]] | [[Intel]] | [[M&M/Mars]] | [[McDonald's]] | [[Merck]] | [[Novartis]] | [[PGA]] | [[Pfizer]] | [[Seagram's]] (Absolut) | [[Sears]] | [[Smuckers]] | [[Sony]] | [[Taco Bell]]
  
 
==Personnel==
 
==Personnel==
 +
===Executive team===
 +
*[[Donna Imperato]], Chief Executive Officer, Cohn & Wolfe Worldwide
 +
*[[Tom Petrosini]], Chief Finance Officer, Cohn & Wolfe Worldwide
 +
*[[Robert Walsh]], Chief Information Officer, Cohn & Wolfe Worldwide
 +
*[[Jill Tannenbaum]], Chief Marketing Officer, Cohn & Wolfe Worldwide
 +
*[[Stephanie Howley]], Senior Vice President, Human Resources, Cohn & Wolfe Worldwide
  
===Senior Management Team===
+
===Regional and market leaders===
*[[Doug Buemi]], Vice Chairman, Cohn & Wolfe Worldwide
+
*[[Almudena Alonso]], Managing Director, Madrid
*[[Sarah Descher]], account manager, Cohn & Wolfe London
+
*[[Stephen Brown]], Managing Director, Atlanta
*[[Christiane Dirkes]], Managing Director, Cohn & Wolfe Frankfurt
+
*[[Doug Buemi]], Vice Chairman, Regional Director, Asia Pacific
*[[Victoria Dix]], Managing Director, Cohn & Wolfe Geneva
+
*[[Mischa Dunton]], Managing Director, San Francisco
*[[Patricia Godefroy]], EVP, General Manager, Cohn & Wolfe Los Angeles
+
*[[Gavin Foo]], Group Managing Director, Southeast Asia
*[[Franco Guzzi]], Managing Director, Cohn & Wolfe Milan
+
*[[Andrew Goldman]], Managing Director, Indonesia
*[[Donna Imperato]], President and CEO, Cohn & Wolfe Worldwide
+
*[[Roberto Gonzalez]], President, Mexico
*[[Jean-François LeBrun]], EVP, General Manager, Cohn & Wolfe Montreal
+
*[[Erik Graadt van Roggen]], Managing Director, Benelux
*[[Annie Longsworth]], Managing Director, Cohn & Wolfe San Francisco
+
*[[Nicky Guertin]], President, Paris
*[[Michael O'Brien]], President, General Manager, Cohn & Wolfe New York
+
*[[Franco Guzzi]], President, Milan
*[[Carol J. Panasiuk]], EVP, General Manager, Cohn & Wolfe Toronto
+
*[[Karen Ho]], Group Managing Director, Southeast Asia
*[[Rose de la Pascua]], Managing Director, Cohn & Wolfe Madrid
+
*[[Brooke Hovey]], Digital Innovation Group - Americas; Managing Director, Austin
*[[Tom Petrosini]], CFO, Cohn & Wolfe Worldwide
+
*[[Jim Joseph]], President, North America
 +
*[[Marta Karlqvist]], President, Nordics
 +
*[[Rafi Q Khan]], CEO, India
 +
*[[Adrian Lee]], Group Managing Director, Southeast Asia
 +
*[[Marina Leung]], Managing Director and Chief Branding Officer, Greater China
 +
*[[Nitin Puri]], CEO, Middle East
 +
*[[Megha Sharma]], Senior Advisor, New Delhi
 +
*[[Lydia Shen]], Managing Director, China
 +
*[[Elena Silva]], Managing Director, Milan
 +
*[[Robyn de Villiers]], Managing Director, Africa
 +
*[[Carol Wang]], Managing Director, Beijing
 +
*[[Scott Wilson]], CEO, London
 
*[[Jonathan Shore]], Managing Director, Cohn & Wolfe London
 
*[[Jonathan Shore]], Managing Director, Cohn & Wolfe London
  
 +
===Practice and industry leaders===
 +
*[[Jeremy Baka]], Chief Creative Catalyst
 +
*[[Geoff Beattie]], Global Corporate Affairs Practice
 +
*[[Liz Beck]], U.S. Consumer Practice
 +
*[[Steve Bonsignore]], U.S. Sports Marketing Practice
 +
*[[Lynn Fisher]], Global Brand Planning & Evaluation
 +
*[[Brooke Hovey]], Digital Innovation Group - Americas; Managing Director, Austin
 +
*[[Mike Kan]], Global Healthcare Practice
 +
*[[Chad Latz]], Global Digital Innovation Group
 +
 +
Healthcare: [[Linda Dyson]] Healthcare Practice Leader
 +
 +
===PRCA lobbying register===
 +
====December 2015-February 2016====
 +
[[Andrew Escott]] | [[Anna Price]] | [[Ben Castrillon]] | [[Eleanor Wilcox]] | [[Katy Richardson]] | [[Rory Fletcher]] <ref name="PRCA"/>
 +
====September 2015-November 2015====
 +
[[Andrew Escott]] | [[Anna Price]] | [[Ben Castrillon]] | [[Eleanor Wilcox]] | [[Katy Richardson]] | [[Rory Fletcher]] <ref name="Sep15"/>
 +
====June 2015-August 2015====
 +
[[Andrew Escott]] | [[Anna Price]] | [[Ben Castrillon]] | [[Eleanor Wilcox]] | [[Katy Richardson]] | [[Rory Fletcher]] <ref name="Jun15"/>
 +
====March 2015-May 2015====
 +
[[Andrew Escott]] | [[Anna Price]] | [[Ben Castrillon]] | [[Eleanor Wilcox]] | [[Katy Richardson]] | [[Rory Fletcher]] <ref name="Mar15"/>
  
 +
===Former people===
 +
*[[Sarah Descher]], account manager, Cohn & Wolfe London. Is now global corporate communications manager at [[Pernod Ricard Winemakers]]
 +
*[[Christiane Dirkes]], managing director, Cohn & Wolfe Frankfurt
 +
*[[Victoria Dix]], managing director, Cohn & Wolfe Geneva. Now head of media relations at [[Trafigura]]
 +
*[[Patricia Godefroy]], EVP, General Manager, Cohn & Wolfe Los Angeles. Now associate dean, marketing and communications at [[UCLA Anderson School of Management]]
 +
*[[Jean-François LeBrun]], EVP, General Manager, Cohn & Wolfe Montreal
 +
*[[Annie Longsworth]], Managing Director, Cohn & Wolfe San Francisco. Is now CEO of [[Saatchi & Saatchi S]] North America <ref> Adam Werbach [http://www.saatchis.com/annie-longsworth-appointed-north-america-ceo-of-saatchi-s-2/ Annie Longsworth Appointed North America CEO of Saatchi S] ''Saatchis'', 9 January 2012, accessed 21 October 2014 </ref>
 +
*[[Michael O'Brien]], President, General Manager, Cohn & Wolfe New York. Left to be appointed executive vice president and director, New York client service, at [[Ketchum]].<ref> [http://www.ketchum.com/nb/news/michael-o%E2%80%99brien-rejoins-ketchum-executive-vice-president-director-new-york-client-service Michael O’Brien Rejoins Ketchum as Executive Vice President, Director, New York Client Service] ''Ketchum'', 9 March 2009, accessed 21 October 2014 </ref>
 +
*[[Carol J. Panasiuk]], EVP, General Manager, Cohn & Wolfe Toronto. Is now principal at the [[Communications Department]].<ref> [http://ca.linkedin.com/pub/carol-panasiuk-mba-apr-fcprs-cmc/8/41/3b Carol Panasiuk] ''Linkedin'', accessed 21 October 2014 </ref>
 +
*[[Rose de la Pascua]], Managing Director, Cohn & Wolfe Madrid. Is now head of [[Weber Shandwick]], Spain.<ref> Patrick Smith [http://www.prweek.com/article/1009878/rose-de-la-pascua-leaves-cohn---wolfe-head-weber-shandwick-spain Rose de la Pascua leaves Cohn & Wolfe to head up Weber Shandwick, Spain] ''PR Week'', 14 June 2014, accessed 21 October 2014 </ref>
  
 
==Contact details==
 
==Contact details==
Cohn & Wolfe London<br>
+
:Address:
7-12 [[Tavistock Square]]<br>
+
:Cohn & Wolfe London/EMEA
Lynton House<br>
+
:7-12 Tavistock Square
London, WC1H 9LT
+
:Lynton House
 +
:London, WC1H 9LT
 +
:United Kingdom
 +
 
 +
:Phone:
 +
:+44 (0)207 331 5300
 +
:Fax: +44 (0)207 331 9083
 +
 
 +
:Website:
 +
:http://www.cohnwolfe.com/
  
 
292 [[Madison Avenue]] <br>
 
292 [[Madison Avenue]] <br>
 
New York, NY 10017<br>
 
New York, NY 10017<br>
 
Phone: 212.798.9700<br>
 
Phone: 212.798.9700<br>
 
Web: http://www.cohnwolfe.com
 
  
 
==Resources==
 
==Resources==
  
*[[Cohn and Wolfe PRCA Yearbook]]
+
*[[Cohn and Wolfe PRCA Yearbook]] 2004
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 
[[Category: Public relations firms]][[Category:Lobbying firms]]
 
[[Category: Public relations firms]][[Category:Lobbying firms]]
[[Category:Food lobbyists and PR consultants]]
+
[[Category:Food lobbyists and PR consultants]][[Category:Pharma]]
 +
[[Category: Big Pharma]]

Latest revision as of 09:18, 5 May 2016

Foodspin badge.png This article is part of the Foodspin project of Spinwatch.
Pharma badge.jpg This article is part of the Pharma_Portal project of Spinwatch.

Cohn and Wolfe - a subsidiary of WPP - describes itself as a "strategic marketing public relations firm dedicated to creating, building and protecting the world's most prolific brands."[1] It has offices all over the world including UK, US, throughout Europe, Latin America, Middle East, and the Asia Pacific region.

The firm claims to be an agency for the 'new communications landscape'. It is a global public relations agency with 50 offices in major markets around the world. They 'offer a powerful combination of breakthrough, brand-building creativity and pioneering digital and social media strategies.' [2]

The firm's 10 industry practices are Consumer Branding, Corporate, Digital, Energy, Entertainment, Healthcare, Public Affairs, Sports Marketing, Sustainability and Technology.

It offers clients 'strategic partnerships' with other WPP companies, including Quinn Gillespie, a lobbying firm.

Cohn and Wolfe has also teamed up with lobbying firm Open Road in the UK. [3]

Healthcare

Cohn and Wolfe recognise that Healthcare PR is changing and encourage clients to search for new models in communicating effectively to healthcare professionals, consumers and payors. The agency in turn creates 'bold creative strategies' with a focus on providing consumers with more information to take more active roles in their healthcare. According to C & W: 'As public relations professionals, it's our job to really understand the conversations happening among our clients' customers, patients, physicians, policy makers, and payors. Much of today's conversation is happening in social media channels, and this is true for healthcare.'[4] The agency claims to be an expert in working in the complex environment where healthcare providers, patients, caregivers, advocacy groups and manufacturers engage in digital communications channels like social communities, blogs, and various audio/video sites.

Dabbling with fake blogging

Fake blogs - a form of viral marketing in which PR or advertising agencies attempt to generate interest in their client's product by creating a fictional character on the internet - are drawing criticism from real bloggers. Cohn & Wolfe apologized in 2005 after "using a fictional character to leave a series of thinly veiled advertisements on blogs and other websites. A number of websites were hit last week with messages from Barry Scott," a fictional spokesman for a British household cleaning product.

British blogger Tom Coates was especially outraged and called it "a new low for marketers" after he wrote an emotional account of his relationship with his father, and then received comment spam from "Barry Scott" disguised as condolences. Coates replied: "My view was that any right-thinking person would view trying to market your product on such a post as revolting, corrupt, cynical, disgusting, sick and dishonourable."[5][6][7]

Ghost-written journal articles

Cohn & Wolfe was at the centre of a scandal in which Eli Lilly (a Cohn & Wolfe client) officials ghost-wrote studies for medical journals. The articles plugged an Eli Lilly drug, the antipsychotic Zyprexa, and were published under the names of credentialed scientists.[8]

Zyprexa is controversial because it is administered by internal injection and is sometimes given forcibly to psychiatric patients. It is also controversial because of its severe listed side-effects, which can include diabetes and tardive dyskinesia (involuntary movements of the mouth, tongue, jaw, or eyelids). The latter side-effect is in some cases irreversible.[9]

In spite of these drawbacks, Lilly sought to make Zyprexa “the number one selling psychotropic in history,” Bloomberg.com reports. In order to make the drug attain its "sales goal", Eli Lilly hired ghost-writers to prepare the articles for publication in medical journals. Documents unsealed as a result of a lawsuit against Eli Lilly for overpricing its drugs reveal that Cohn & Wolfe played a PR role in this process.

Bloomberg.com reports:

“The paper for the Progress in Neurology and Psychiatry supplement has been completed and sent to the journal for peer review,” Kerrie Mitchell, an employee of the public relations agency Cohn & Wolfe, wrote in a Feb. 23, 2001, e-mail to Michael Sale, a Lilly marketing official. The message was among the unsealed files.
“We ‘ghost’ wrote this article and then worked with author Dr. Haddad to work up the final copy,” Mitchell said in the e- mail. Eric Litchfield, a spokesman for Cohn & Wolfe, didn’t immediately return a call seeking comment... Peter Haddad, a researcher at Greater Manchester West Mental Health NHS Foundation Trust in the U.K., was listed as the article’s lead author. [10]

Rebranding shyness as national disease problem

According to a story by Martha Rosenberg on AlterNet, Cohn & Wolfe is credited with rebranding shyness as a disease that requires medication with the drug Paxil:

Slick PR firm Cohn and Wolfe is credited with vaulting "shyness" to a national psychiatric problem, the answer for which is Paxil, and creating faux grassroots patient groups like Freedom From Fear to push their clients' drugs.[11]

Paxil is an antidepressant drug of the SSRI (selective serotonin reuptake inhibitor) type, manufactured by GlaxoSmithKline. It became controversial after a Wyoming, USA lawsuit in 2001 brought against GlaxoSmithKline. The jury decided that Paxil was implicated in a tragic case where a 60-year-old man, Donald Schell, shot and killed his wife, daughter and granddaughter and then himself after taking Paxil for only two days. The jury, assisted by the expert testimony of Dr David Healy, a well known critic of SSRIs, concluded that Paxil "can cause some people to become homicidal and/or suicidal." GlaxoSmithKline was ordered to pay the plaintiffs, members of Mr Schell's family, $8 million.[12]

Clients

PRCA lobbying register

December 2015-Feburary 2016

3M | Asia Pulp and Paper | Ferrero UK Ltd | Lloyds Banking Group | Scottish Widows | Warburtons [13]

September 2015-November 2015

3M | Asia Pulp and Paper | Ferrero UK Ltd | Lloyds Banking Group | Scottish Widows | Warburtons [14]

June 2015-August 2015

3M | Asia Pulp and Paper | Ferrero UK Ltd | Lloyds Banking Group | Scottish Widows | Warburtons [15]

March 2015-May 2015

3M | Asia Pulp and Paper | Ferrero UK Ltd | Lloyds Banking Group | Scottish Widows | Warburtons [16]

2009

As of June 2009 O'Dwyer's Directory of PR Firms lists Cohn & Wolfe clients as including:[17] 3M | ADP | American Foundation for Suicide Prevention | Chevron Texaco | Coca-Cola | Colgate-Palmolive | Danone | Diageo | DuPont | Eli Lilly & Co. | Epson | Hewlett-Packard | Hilton Hotels | Illycafe | Intel | M&M/Mars | McDonald's | Merck | Novartis | PGA | Pfizer | Seagram's (Absolut) | Sears | Smuckers | Sony | Taco Bell

Personnel

Executive team

Regional and market leaders

Practice and industry leaders

Healthcare: Linda Dyson Healthcare Practice Leader

PRCA lobbying register

December 2015-February 2016

Andrew Escott | Anna Price | Ben Castrillon | Eleanor Wilcox | Katy Richardson | Rory Fletcher [13]

September 2015-November 2015

Andrew Escott | Anna Price | Ben Castrillon | Eleanor Wilcox | Katy Richardson | Rory Fletcher [14]

June 2015-August 2015

Andrew Escott | Anna Price | Ben Castrillon | Eleanor Wilcox | Katy Richardson | Rory Fletcher [15]

March 2015-May 2015

Andrew Escott | Anna Price | Ben Castrillon | Eleanor Wilcox | Katy Richardson | Rory Fletcher [16]

Former people

Contact details

Address:
Cohn & Wolfe London/EMEA
7-12 Tavistock Square
Lynton House
London, WC1H 9LT
United Kingdom
Phone:
+44 (0)207 331 5300
Fax: +44 (0)207 331 9083
Website:
http://www.cohnwolfe.com/

292 Madison Avenue
New York, NY 10017
Phone: 212.798.9700

Resources

References

  1. Cohn & Wolfe website
  2. Cohn & Wolfe. Cohn & Wolfe About Us. Accessed on 24 October 2009.
  3. APPC register, 12 2006 - 03 2007
  4. Cohn & Wolfe. Cohn & Wolfe Practices. Accessed on 24 October 2009.
  5. Tom Coates, On Cillit Bang and a new low for marketers...", Plasticbag.org, September 30, 2005.
  6. An apology from the Cillit Bang team...", Plasticbag.org, October 4, 2005
  7. Bobbie Johnson, "Cleaner caught playing dirty on the net", The Guardian (UK), October 6, 2005
  8. Elizabeth Lopatto, Jef Feeley and Margaret Cronin Fisk, "Eli Lilly "ghost-wrote" articles to market Zyprexa, files show", Bloomberg, 123 June 2009, accessed 23 June 2009
  9. Zyprexa, Zydis, MedicineNet.com, accessed 23 June 2009
  10. Elizabeth Lopatto, Jef Feeley and Margaret Cronin Fisk, "Eli Lilly "ghost-wrote" articles to market Zyprexa, files show", Bloomberg, 123 June 2009, accessed 23 June 2009
  11. Martha Rosenberg, Are You One of Big Pharma's Lab Animals?, AlterNet, 7 December 2007, accessed June 23 2009
  12. Evelyn Pringle, "Uphill Battle - Warning Pharma Customers about Dangers of SSRIs", lawyersandsettlements.com, 29 September 2006, accessed 23 June 2009
  13. 13.0 13.1 Cohn and Wolfe clients, Dec15-Feb16, PRCA, accessed 4 May 2016
  14. 14.0 14.1 Cohn and Wolfe Ltd client list, Sep-Nov15, PRCA, accessed 5 May 2016
  15. 15.0 15.1 Cohn and Wolfe Ltd client list, Jun-Aug15, PRCA, accessed 5 May 2016
  16. 16.0 16.1 Cohn & Wolfe Ltd client list, Mar-May15, PRCA, accessed 5 May 2016
  17. Cohn & Wolfe, O'Dwyer's, accessed 17 June 2009
  18. Adam Werbach Annie Longsworth Appointed North America CEO of Saatchi S Saatchis, 9 January 2012, accessed 21 October 2014
  19. Michael O’Brien Rejoins Ketchum as Executive Vice President, Director, New York Client Service Ketchum, 9 March 2009, accessed 21 October 2014
  20. Carol Panasiuk Linkedin, accessed 21 October 2014
  21. Patrick Smith Rose de la Pascua leaves Cohn & Wolfe to head up Weber Shandwick, Spain PR Week, 14 June 2014, accessed 21 October 2014